Literature DB >> 1335042

Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor.

L H Elliott1, W H Brooks, T L Roszman.   

Abstract

Previously we have reported that human glial tumor cells secrete a factor(s) which suppresses the mitogen responsiveness of normal human peripheral blood lymphocytes (PBL) in a dose dependent manner. In this study we extend these observations and explore the possible mechanisms by which glioma-derived suppressor factor(s) (GSF) modulates lymphocyte reactivity. Preincubation of lymphocytes with GSF for 2 hrs induces suppression of lymphocyte mitogen responsiveness. GSF also inhibits production of interleukin-2 (IL-2) by mitogen activated human T-cells. Addition of delectinated or recombinant IL-2 to mitogen activated human T-cells in the presence of GSF does not restore the normal proliferative response of these cells. These findings suggest that GSF induces a defect in the expression of the receptor for IL-2 (IL-2R) on activated T-cells. Binding studies with radiolabeled IL-2 demonstrated that GSF suppresses and in some cases completely inhibits the expression of functional high affinity IL-2R on activated T-cells, thereby, preventing association of IL-2R with its receptor and the subsequent progression of the cell into the proliferative stage of the cell cycle. These cellular defects induced by GSF closely parallel the observed defects noted in T-cells obtained from patients with gliomas, indicating that the factors elicited from glial tumors may be responsible for the immunological deficits observed in patients with primary malignant intracranial tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335042     DOI: 10.1007/bf00170940

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor.

Authors:  T L Roszman; W H Brooks; L H Elliott
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Malignant glioma modulation of immune function: relative contribution of different soluble factors.

Authors:  W T Couldwell; P Dore-Duffy; M L Apuzzo; J P Antel
Journal:  J Neuroimmunol       Date:  1991-08       Impact factor: 3.478

5.  Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status.

Authors:  W H Brooks; R B Latta; M S Mahaley; T L Roszman; L Dudka; C Skaggs
Journal:  J Neurosurg       Date:  1981-03       Impact factor: 5.115

6.  Prostaglandin and thromboxane synthesis by human intracranial tumors.

Authors:  M G Castelli; C Chiabrando; R Fanelli; L Martelli; G Butti; P Gaetani; P Paoletti
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

7.  The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.

Authors:  C Siepl; S Bodmer; K Frei; H R MacDonald; R De Martin; E Hofer; A Fontana
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

8.  Expression of platelet-derived growth factors, transforming growth factors, and the ros gene in a variety of primary human brain tumors.

Authors:  T Mapstone; M McMichael; D Goldthwait
Journal:  Neurosurgery       Date:  1991-02       Impact factor: 4.654

9.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  9 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules.

Authors:  A Salmaggi; A Dufour; A Silvani; E Ciusani; A Nespolo; A Boiardi
Journal:  Ital J Neurol Sci       Date:  1996-08

Review 3.  Arboviruses and the central nervous system.

Authors:  D E Griffin
Journal:  Springer Semin Immunopathol       Date:  1995

Review 4.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

5.  Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression.

Authors:  A M Donson; N K Foreman
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 6.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

7.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

Authors:  H Fakhrai; O Dorigo; D L Shawler; H Lin; D Mercola; K L Black; I Royston; R E Sobol
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

8.  Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

Authors:  P A Ruffini; L Rivoltini; A Silvani; A Boiardi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

9.  GLI2 regulates TGF-β1 in human CD4+ T cells: implications in cancer and HIV pathogenesis.

Authors:  Robert L Furler; Christel H Uittenbogaart
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.